Ixico PLC | Cash Flow

Fiscal year is October-September. All values GBP Thousands.
2012
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,766.30
2,292.00
1,194.00
2,119.00
1,527.00
668
Depreciation, Depletion & Amortization
26.90
181.00
149.00
347.00
192.00
152
Other Funds
5,899.50
103.00
-
-
-
318
Funds from Operations
8,299.20
1,061.00
846.00
1,498.00
774.00
198
Changes in Working Capital
382.10
1,195.00
469.00
36.00
130.00
561
Net Operating Cash Flow
8,681.30
2,256.00
1,315.00
1,534.00
644.00
363
Capital Expenditures
5.90
125.00
45.00
24.00
49.00
Sale of Fixed Assets & Businesses
-
-
-
98.00
-
Net Investing Cash Flow
5.90
4,372.00
45.00
74.00
49.00
Net Financing Cash Flow
5,899.40
319.00
-
2,706.00
-
Net Change in Cash
2,787.80
2,435.00
1,360.00
1,186.00
706.00
Free Cash Flow
8,687.20
2,381.00
1,360.00
1,558.00
693.00
Other Sources
-
4,497.00
-
-
-
Change in Capital Stock
0.10
216.00
-
2,706.00
-
Exchange Rate Effect
-
-
-
60.00
13.00

About Ixico

View Profile
Address
Griffin Court
London Greater London EC1A 9PN
United Kingdom
Employees -
Website http://ixico.com/
Updated 07/08/2019
IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was founded by Derek Lionel Glendon Hill on November 28, 1995 and is headquartered in London, the United Kingdom.